Toremifene in the treatment of breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 393-405

  Mustonen, Mika Vj ^a   Pyrhönen, Seppo ^b   Kellokumpu Lehtinen, Pirkko Liisa ^c  

^a ORION CORPORATION   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Adjuvant treatment; Advanced breast cancer; Breast cancer; Tamoxifen; Toremifene

Indexed keywords

EID: 84912136441     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.393     Document Type: Review

References (79)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011; 61: 409-418 [PMID: 21969133 DOI: 10.3322/caac.20134]
2. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012; 36: 237-248 [PMID: 22459198 DOI: 10.1016/j.canep.2012.02.007]
3. Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: An ageperiod-cohort analysis. Br J Cancer 2002; 87: 982-988 [PMID: 12434289 DOI: 10.1038/sj.bjc.6600583]
4. Nagata C, Kawakami N, Shimizu H. Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat 1997; 44: 75-82 [PMID: 9164680]
5. Lim SE, Back M, Quek E, Iau P, Putti T, Wong JE. Clinical observations from a breast cancer registry in Asian women. World J Surg 2007; 31: 1387-1392 [PMID: 17510768 DOI: 10.1007/s00268-007-9086-3]
6. Lester J. Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 2007; 11: 619-622 [PMID: 17962169 DOI: 10.1188/07.CJON.619-622]
7. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 2013; 5: S2-S8 [PMID: 23819024]
8. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) Program populationbased study. Arch Intern Med 2002; 162: 1985-1993 [PMID: 12230422 DOI: 10.1001/archinte.162.17.1985]
9. Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, Verdecchia A, Faivre J, Hakulinen T, Coebergh JW, Martinez-Garcia C, Forman D, Zappone A. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659-1667 [PMID: 11527693]
10. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315-317 [PMID: 8435874 DOI: 10.1093/carcin/14.2.315]
11. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919-3924 [PMID: 8358718]
12. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, Mc-Gann-Maloney E, Perlman JA, Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 1654-1662 [PMID: 10511593 DOI: 10.1093/jnci/91.19.1654]
13. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-537 [PMID: 8133536 DOI: 10.1093/jnci/86.7.527]
14. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299-1306 [PMID: 1886157 DOI: 10.1093/jnci/83.18.1299]
15. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87: 645-651 [PMID: 7752269 DOI: 10.1093/jnci/87.9.645]
16. Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, Miura S, Takashima S, Mitsuyama S, Ueo H, Ohashi Y. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 2000; 11: 1537-1543 [PMID: 11205460]
17. Pukkala E, Kyyrönen P, Sankila R, Holli K. Tamoxifen and toremifene treatment of breast cancer and risk of subse-quent endometrial cancer: A population-based case-control study. Int J Cancer 2002; 100: 337-341 [PMID: 12115550 DOI: 10.1002/ijc.10454]
18. Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumours. An update. Drug Saf 1997; 16: 104-117 [PMID: 9067122 DOI: 10.2165/00002018-199716020-00003]
19. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-Analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937-947 [PMID: 14687281 DOI: 10.1046/j.1525-1497.2003.20724.x]
20. Hellmann-Blumberg U, Cartner MG, Wurz GT, DeGregorio MW. Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA. Breast Cancer Res Treat 1998; 50: 135-141 [PMID: 9822218]
21. Kuramochi H. Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J Med Chem 1996; 39: 2877-2886 [PMID: 8709121 DOI: 10.1021/jm960255g]
22. Homesley HD, Shemano I, Gams RA, Harry DS, Hickox PG, Rebar RW, Bump RC, Mullin TJ, Wentz AC, OToole RV. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 1993; 16: 117-122 [PMID: 8452102 DOI: 10.1097/00000421-199304000-00007]
23. Kivinen S, Menp J. Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study. J Steroid Biochem 1990; 36: 217-220 [PMID: 2142236 DOI: 10.1016/002 2-4731(90)90008-G]
24. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 1988; 24: 785-790 [PMID: 2968265 DOI: 10.1016/0277-5 379(88)90316-1]
25. Modig H, Borgström S, Nilsson I, Westman G. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J Steroid Biochem 1990; 36: 235-236 [PMID: 2142242]
26. Gundersen S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J Steroid Biochem 1990; 36: 233-234 [PMID: 2142241]
27. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti LR, Hajba A. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 1990; 36: 227-228 [PMID: 2142239 DOI: 10.1016/0022-4731(90)90011-G]
28. Valavaara R, Pyrhönen S. Low-dose toremifene in the treatment of estrogen-receptor-positive advanced breast cancer in postmenopausal women. Curr Ther Res 1989; 46: 966-973
29. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13: 2556-2566 [PMID: 7595707]
30. Zejnalov RS, Musaev IN, Giyasbejli SR, Dadasheva NR, Gasanzade DA, Yusifov AI, Akhadova NA. Comparative analysis of the efficacy of toremifeine, tamoxifen and letrozole in treatment of patients with disseminated breast cancer. Onkologiya 2006; 8: 1-4
31. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmn J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997; 45: 251-262 [PMID: 9386869]
32. Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the nordic phase III study. Br J Cancer 1997; 76: 270-277 [PMID: 9231932 DOI: 10.1038/bjc.1997.375]
33. Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000; 18: 3487-3494 [PMID: 11032589]
34. Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001; 65: 119-124 [PMID: 11261827]
35. Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004; 15: 1749-1759 [PMID: 15550579]
36. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, Mc-Masters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010; 116: 2307-2315 [PMID: 20209619]
37. Kimura M, Tominaga T, Kimijima I, Takatsuka Y, Takashima S, Nomura Y, Kasumi F, Yamaguchi A, Masuda N, Noguchi S, Eshima N. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer. Breast Cancer 2014; 21: 275-283 [PMID: 22968626]
38. Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Saji S, Yamamoto-Ibusuki M, Iwase H. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer 2013; 13: 239 [PMID: 23679192]
39. Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer-A comparative study by a double blind method with tamoxifen]. Gan To Kagaku Ryoho 1993; 20: 247-258 [PMID: 8434963]
40. Gu R, Jia W, Zeng Y, Rao N, Hu Y, Li S, Wu J, Jin L, Chen L, Long M, Chen K, Chen L, Xiao Q, Wu M, Song E, Su F. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: A retrospective cohort study. BMC Cancer 2012; 12: 161 [PMID: 22548922]
41. Qin T, Yuan ZY, Peng RJ, Zeng YD, Shi YX, Teng XY, Liu DG, Bai B, Wang SS. Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: A retrospective analysis. Curr Oncol 2013; 20: 196-204 [PMID: 23904760]
42. Gershanovich M, Hayes DF, Ellmn J, Vuorinen J. Highdose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) 1997; 11: 29-36 [PMID: 9165504]
43. Pyrhönen S, Ellmn J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF. Meta-Analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56: 133-143 [PMID: 10573106]
44. Zhou WB, Ding Q, Chen L, Liu XA, Wang S. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat 2011; 128: 625-631 [PMID: 21553116]
45. Chi F, Wu R, Zeng Y, Xing R, Liu Y, Xu Z. Effects of tore-mifene versus tamoxifen on breast cancer patients: A metaanalysis. Breast Cancer 2013; 20: 111-122 [PMID: 23266963]
46. Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL. Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database Syst Rev 2012; 7: CD008926 [PMID: 22786516]
47. Gylling H, Pyrhönen S, Mntyl E, Menp H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995; 13: 2900-2905 [PMID: 8523053]
48. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429-433 [PMID: 8636753]
49. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000; 63: 225-234 [PMID: 11110056]
50. Kusama M, Miyauchi K, Aoyama H, Sano M, Kimura M, Mitsuyama S, Komaki K, Doihara H. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 2004; 88: 1-8 [PMID: 15538040]
51. Kusama M, Kaise H, Nakayama S, Ota D, Misaka T, Aoki T. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res Treat 2004; 88: 9-16 [PMID: 15538041]
52. Anan K, Mitsuyama S, Yanagita Y, Kimura M, Doihara H, Komaki K, Kusama M, Ikeda T. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: The results of a 2-year multicenter open randomized study. Breast Cancer Res Treat 2011; 128: 775-781 [PMID: 21638048]
53. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83: 1158-1162 [PMID: 9543133]
54. Marttunen MB, Hietanen P, Titinen A, Roth HJ, Viinikka L, Ylikorkala O. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 1999; 65: 365-368 [PMID: 10541761]
55. Tiitinen A, Nikander E, Hietanen P, Mets-Heikkil M, Ylikorkala O. Changes in bone mineral density during and after 3 years use of tamoxifen or toremifene. Maturitas 2004; 48: 321-327 [PMID: 15207898 DOI: 10.1016/j.maturitas.2004.02.018]
56. Saarto T, Blomqvist C, Vlimki M, Mkel P, Sarna S, Elomaa I. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997; 75: 602-605 [PMID: 9052418 DOI: 10.1038/bjc.1997.105]
57. Saarto T, Vehmanen L, Elomaa I, Vlimki M, Mkel P, Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001; 84: 1047-1051 [PMID: 11308252 DOI: 10.1054/bjoc.2001.1729]
58. Erkkola R, Mattila L, Powles T, Heikkinen J, Toivola B, Korhonen P, Mustonen M. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre-And post-menopausal women. Breast Cancer Res Treat 2005; 93: 277-287 [PMID: 16172794 DOI: 10.1007/s10549-005-5701-x]
59. Harvey HA, Kimura M, Hajba A. Toremifene: An evaluation of its safety profile. Breast 2006; 15: 142-157 [PMID: 16289904 DOI: 10.1016/j.breast.2005.09.007]
60. Marttunen MB, Cacciatore B, Hietanen P, Pyrhönen S, Tiitinen A, Wahlström T, Ylikorkala O. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001; 84: 897-902 [PMID: 11286468 DOI: 10.1054/bjoc.2001.1703]
61. Hirsimki P, Hirsimki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch Toxicol 1993; 67: 49-54 [PMID: 8452480 DOI: 10.1007/BF02072035]
62. Brown K. Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 2009; 24: 391-404 [PMID: 19505894 DOI: 10.1093/mutage/gep022]
63. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res 1993; 53: 4534-4541 [PMID: 8402624]
64. Hemminki K, Widlak P, Hou SM. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995; 16: 1661-1664 [PMID: 7614704 DOI: 10.1093/carcin/16.7.1661]
65. Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YR, Kanno Y, Suzuki M, Apak TI, Sheng JJ, Duffel MW. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 2001; 61: 3925-3931 [PMID: 11358807]
66. Gamboa da Costa G, Pereira PC, Churchwell MI, Beland FA, Marques MM. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. Chem Res Toxicol 2007; 20: 300-310 [PMID: 17261033]
67. Harvey H, Hajba A. Stroke incidence with toremifene is lower than with tamoxifen in breast cancer patients. Proc ASCO 2003; 22: 741 (Abstract 2981)
68. Asaishi K, Tominaga T, Abe O, Izuo M, Nomura Y. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer]. Gan To Kagaku Ryoho 1993; 20: 91-99 [PMID: 8422190]
69. Gams RA, Hajba A. High-dose toremifene in the management of advanced breast cancer refractory to tamoxifen and other therapies. Florida, USA: ASCO, Orlando, 2002
70. Pyrhönen S, Valavaara R, Vuorinen J, Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994; 29: 223-228 [PMID: 8049456 DOI: 10.1007/BF00666475]
71. Hietanen T, Hakala T, Baltina D, Johansson R, Numminen S, Helle L, Valavaara R, Thölix E. Open phase II study of highdose toremifene as first-line therapy for advanced breast cancer. Oncology (Williston Park) 1997; 11: 37-40 [PMID: 9165505]
72. Yamamoto Y, Kawazoe T, Iwase H. [Experience of highdose toremifene treatment for postmenopausal women with metastatic breast cancer]. Gan To Kagaku Ryoho 2005; 32: 1415-1419 [PMID: 16227740]
73. Ohtake T, Yasuda M, Watanabe K, Ito T, Ito J, Miyamoto K, Yoshida S, Abe N, Ishigame T, Ishii M, Kimijima I, Takenoshita S. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors]. Gan To Kagaku Ryoho 2009; 36: 1459-1463 [PMID: 19755813]
74. Okita A, Saeki T, Aogi K, Osumi S, Takashima S, Okita R, Taira N, Kakishita T, Kurita A. Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. Acta Med Okayama 2009; 63: 187-194 [PMID: 19727203]
75. Koyama H, Iesato A, Fukushima Y, Okada T, Watanabe T, Harada M, Ito T, Maeno K, Mochizuki Y, Ito K, Amano J. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer]. Gan To Kagaku Ryoho 2011; 38: 1123-1126 [PMID: 21772095]
76. Sawaki M, Wada M, Sato Y, Mizuno Y, Kobayashi H, Yokoi K, Yoshihara M, Kamei K, Ohno M, Imai T. High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study. Oncol Lett 2012; 3: 61-65 [PMID: 22740857]
77. Tokura H, Fujisaki M, Takahashi T, Takigawa Y, Onouchi S, Matsuda K, Hirata A. [A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer]. Gan To Kagaku Ryoho 2012; 39: 1071-1073 [PMID: 22790041]
78. Koike K, Edo M, Higaki M, Kitahara K, Satou S, Noshiro H. The clinical benefit of high-dose toremifene for metastatic breast cancer. Gan To Kagaku Ryoho 2013; 40: 877-880 [PMID: 23863727]
79. Ogata H, Okamoto Y, Arima Y, Fukushima H, Takeyama H, Yamashita A, Kinoshita M, Suzuki N, Sawada T, Koshida Y, Matsui A, Tachibana A, Nakayama H, Oishi Y, Nogi H, Uchida K. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer. Gan To Kagaku Ryoho 2013; 40: 749-753 [PMID: 23863651]